Judge Blocks Rival Botox Drug In Trade Secrets Trial

Law360, Los Angeles (March 07, 2012, 9:18 PM ET) -- A California federal judge on Tuesday barred Merz Pharmaceuticals LLC from selling wrinkle-reducing drug Xeomin, just days before the Botox competitor’s nationwide launch, in a bench trial over allegations the company's employees stole trade secrets from Botox maker and rival Allergan Inc.

U.S. District Judge Andrew J. Guilford issued the order after closing arguments in the 11-day bench trial Tuesday, according to a court official, saying he will issue a written order setting out the full terms and duration of the injunction Friday.

Tuesday’s ruling marked...
To view the full article, take a free trial now.
Try Law360 for free for seven days
Already a subscriber? Click here to login

Already have access?

  1. Forgot your password?
  2. Sign In

Get instant access to the one-stop news source for business lawyers